The Global Primary Immunodeficiency Diseases (PIDD) Market is consolidated with CSL Behring LLC and Grifols S.A. holding a collective share of 60.5% in 2014, states Transparency Market Research (TMR) in its latest report. Other leading players within the market are Octapharma AG and Baxter International, Inc. These companies are primarily capitalizing on the growing incidences of immunodeficiency diseases and investing extensively on the research and development so as to come up with new and effective treatment options. The growing R&D investments by leading market players are helping them maintain their strong foothold in the primary immunodeficiency diseases market. In addition to this, increased funding for pharmaceutical and biopharmaceutical research will encourage market players to continue on their mission to develop effective treatment solutions.
According to the report by TMR, global primary immunodeficiency diseases market will be worth US$7.5 bn by the end of 2023. On the basis of geography, Europe and North America are leading. Asia Pacific will emerge as an attractive market for primary immunodeficiency diseases. On the basis of treatment, the immunoglobulin replacement segment is predicted to witness an exponential rise in the years to come. There will also be a rise in the demand for stem cell and gene therapy for PIDD treatment.
Undetected Cases due to Inadequate Provision for Diagnosis of PIDD to Pose a Key Challenge
Inadequate and unfavorable reimbursement policies in many nations will hamper the growth of the global primary immunodeficiency diseases market. The absence of adequate provision for diagnosis of PIDD among newborns will restrict the growth of this market. Many cases go undetected in developing nations. “Of the 10 mn people who actually suffer from primary immunodeficiency diseases, thousands of adult cases also go undiagnosed, acting as a major challenge for the growth of this market,” states a TMR analyst.
Request to View Brochure of Report -
Growing Awareness Regarding PIDD to Drive Demand
The global primary immunodeficiency diseases market is driven by government approvals and support. The awareness created about PIDD by various government and private organizations will also aid the growth of this market. The demand will witness a positive rise in both developed and developing countries. Unmet medical needs in emerging nations will act as growth opportunity for primary immunodeficiency diseases market, states TMR. Recently many policies have been undertaken by governments across developing countries which work in the favor of this market’s growth. Also, favorable health trends in Asia Pacific will boost the growth of this market.
Comments
Post a Comment